POLTX_FiberNCT07576322
Short-Term Safety and Performance of a Wound Dressing Evaluation
At risk: Primary completion moved at least 4 months later, primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Start date: Jun 15, 2026 to Dec 1, 2026 Show 9 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 117 words
- Primary completion pushed from Jun 14, 2027 to Oct 31, 2027
- Study completion pushed from Sep 30, 2027 to Nov 30, 2027
- Secondary endpoints: 8 to 11
- Study description expanded, about 68 words
- Study sites revised (3)
- Collaborators revised (3)
- Study title revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of adverse events and device deficiencies
Timeframe: 12 Weeks
Percentage wound area reduction from baseline to Day 30
Timeframe: Baseline to Day 30 (±1 day).
Proportion of POLTX_Fiber dressing removals completed in one piece
Timeframe: Baseline through Day 30 (±1 day).
Secondary (11)
Percentage wound area reduction at Weeks 1, 2, 3, 8 and 12
Change in wound tissue composition
Change from baseline in the condition of the skin surrounding the wound
Local infection signs
Investigator assessment of dressing usability and handling
Show 6 moreShow less
Pain intensity before and after dressing changes
Change from baseline in wound exudate amount
Change from baseline in wound exudate colour
Change from baseline in wound exudate odour
Frequency of dressing changes during the treatment period
Patient-reported global tolerability of the dressing
Arms and interventions
POLTX_Fiber armExperimental
POLTX\_Fiber, an absorbent gelling fiber dressing for moderate-high exudate chronic wounds
Suprasorb® Liquacel Pro, CE-marked gelling fiber dressingPlacebo comparator
Suprasorb® Liquacel Pro arm
Combination products: Politix Fiber arm
Sites
3 sites in 1 country